Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) EPS (Weighted Average and Diluted): 2014-2024

Historic EPS (Weighted Average and Diluted) for Lineage Cell Therapeutics (LCTX) over the last 7 years, with Dec 2024 value amounting to -$0.09.

  • Lineage Cell Therapeutics' EPS (Weighted Average and Diluted) fell 550.00% to -$0.13 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.29, marking a year-over-year decrease of 141.67%. This contributed to the annual value of -$0.09 for FY2024, which is 25.00% up from last year.
  • According to the latest figures from FY2024, Lineage Cell Therapeutics' EPS (Weighted Average and Diluted) is -$0.09, which was up 25.00% from -$0.12 recorded in FY2023.
  • Over the past 5 years, Lineage Cell Therapeutics' EPS (Weighted Average and Diluted) peaked at -$0.09 during FY2024, and registered a low of -$0.15 during FY2022.
  • Over the past 3 years, Lineage Cell Therapeutics' median EPS (Weighted Average and Diluted) value was -$0.12 (recorded in 2023), while the average stood at -$0.12.
  • Data for Lineage Cell Therapeutics' EPS (Weighted Average and Diluted) shows a peak YoY increased of 25.00% (in 2024) over the last 5 years.
  • Lineage Cell Therapeutics' EPS (Weighted Average and Diluted) (Yearly) stood at -$0.15 in 2022, then climbed by 20.00% to -$0.12 in 2023, then increased by 25.00% to -$0.09 in 2024.